-
Medtronic Partners with China Resources Guangdong Pharmaceutical at CIIE for Medical Equipment Development
•
US-Irish firm Medtronic (NYSE: MDT) has entered into a partnership with China-based China Resources Guangdong Pharmaceutical Co., Ltd. (HKG: 3320) at the 7th China International Import Expo (CIIE). The collaboration is aimed at developing minimally invasive surgical medical equipment to enhance patients’ diagnosis and treatment experience. Focus on GBA Policy…
-
Everest Medicines’ Velsipity Approved for Use in Select Hospitals in China’s Greater Bay Area
•
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received approval in the Greater Bay Area (GBA) for its drug Velsipity (etrasimod) to be used in Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat-sen University. These medical institutions are part of the…
-
Lundbeck’s Vyepti Migraine Treatment Available at Sun Yat-sen Memorial Hospital Through Greater Bay Area Policy
•
Vyepti (eptinezumab), a migraine treatment developed by Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF), has been introduced at Sun Yat-sen Memorial Hospital, Sun Yat-sen University, facilitated by the “Hong Kong-Macau Drug and Device Access” policy. This policy, part of the broader Greater Bay Area initiative, enables patients to access…
-
AstraZeneca’s Saphnelo Approved for Use in Guangdong Under ‘Hong Kong-Macau Drug Access’ Policy
•
AstraZeneca (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced that its drug Saphnelo (anifrolumab) has been approved by the Guangdong Medical Products Administration (MPA) bureau to be included in medical institutions as part of the “Hong Kong-Macau Drug and Device Access” policy. This policy, within the Greater Bay…
-
Merck KGaA’s Pergoveris Treatment Expands Access to Advanced Reproductive Care in Greater Bay Area
•
Merck KGaA (MRK, NYSE: MRK) , a leading science and technology company based in Germany, has announced the availability of its ovulation-stimulating treatment Pergoveris in the Guangdong–Hong Kong–Macao Greater Bay Area. The treatment, which combines recombinant human follicle stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH), has been approved…
-
AstraZeneca’s Strensiq Approved for Rare Disease Therapy under Greater Bay Area’s Drug Access Policy
•
AstraZeneca (NASDAQ: AZN, LON: AZN) , a leading UK pharmaceutical company, has received approval for its rare disease therapy Strensiq (asfotase alfa) from the Guangdong Medical Products Administration (MPA) bureau. This clearance allows Strensiq to be introduced to medical institutions under the “Hong Kong-Macau Drug and Device Access” policy, a…
-
AstraZeneca’s Strensiq Gains Approval for Rare Disease Therapy in Guangdong Under “Hong Kong-Macau Drug and Device Access”
•
LONDON—AstraZeneca (NASDAQ: AZN, LON: AZN) , a leading UK-based pharmaceutical company, has announced that its rare disease therapy Strensiq (asfotase alfa) has been granted market access by the Guangdong Medical Products Administration (MPA) bureau. This approval is a significant step under the “Hong Kong-Macau Drug and Device Access” policy, which…
-
CNBG and University of Macau Ink Deal to Establish Joint Biotech Lab
•
China National Biotec Group Company Ltd (CNBG) has announced a strategic collaboration with the University of Macau, marking a significant step in the biotech sector. The partnership, formalized with a signing ceremony at the Guangdong-Macao in-depth cooperation zone in Hengqin, aims to leverage the university’s cutting-edge research capabilities and CNBG’s…
-
Luye Pharma Group Secures RMB 1.6 Billion Investment to Boost Financials and R&D
•
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that it has successfully secured RMB 1.6 billion in funding from the Shenzhen Luye Private Equity Investment Fund. This fund is primarily controlled by the Shenzhen Municipal People’s Government State-owned Assets Supervision and Administration Commission. The…
-
Novartis’s Tabrecta Earns NMPA Nod for MET-Positive Advanced NSCLC in China
•
Swiss pharmaceutical titan Novartis has secured marketing approval from China’s National Medical Products Administration (NMPA) for its drug Tabrecta (capmatinib), intended for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a mesenchymal–epithelial transition (MET) exon 14 skipping mutation, who have not received…
-
Hong Kong SAR and NMPA Renew Agreements to Boost Drug and Medical Device Regulation
•
Professor Chung-mau LO, BBS, JP, Secretary for Health of the Hong Kong Special Administrative Region (SAR) government, held a meeting with Li Li, Director of the National Medical Products Administration (NMPA). The meeting focused on enhancing collaboration regarding drug and medical device approval processes, clinical trials, and the advancement of…
-
GBA Center of NMPA Launches Filing Guidance for Pharmaceutical Enterprises
•
The Guangdong-Hong Kong-Macau Greater Bay Area (GBA) Center for Drug Evaluation and Inspection, under the National Medical Products Administration (NMPA), has announced the commencement of filing guidance services for pharmaceutical R&D entities within the GBA. This initiative aligns with the Drug Registration Regulation, aiming to offer technical guidance, facilitate communication,…
-
InnoCare Pharma Reports 2023 Revenue Growth and Pipeline Expansion
•
InnoCare Pharma (HKG: 9969; SHA: 688428), a Beijing-based biotech company, has released its financial report for 2023, recording RMB 739 million (USD 102.2 million) in revenues and RMB 672 million (USD 92.9 million) in product sales, marking increases of 18.09% and 18.5% year-on-year (YOY), respectively. The company’s research and development…
-
Fosun Health and Adventist Medical Center Partner to Enhance GBA Medical Services
•
China-based Fosun Health Consumption Industry Group has entered into a strategic partnership with Hong Kong’s Adventist Medical Center, aiming to leverage their combined resources and expertise to enhance medical services in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Under the terms of the agreement, both organizations will intensify collaboration in…
-
China Unveils Action Plan to Boost Foreign Investment and Open Economy Further
•
The State Council of China has unveiled an ambitious “Action Plan to Promote the High-Level Opening up of China to Global Markets and Attract and Apply Greater Levels of Foreign Investment.” This initiative aims to further integrate China’s economy with global markets and enhance foreign investment inflows. Key measures include…
-
China Resources Guangdong Pharmaceutical Partners with BD to Enhance Drug and Device Distribution in GBA
•
China Resources Guangdong Pharmaceutical Co., Ltd has entered into a strategic partnership with U.S.-based Becton, Dickinson and Co. (BD) to develop a specialized channel for drugs and medical devices in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Under this partnership, China Resources Guangdong Pharmaceutical will capitalize on its strengths to…
-
Everest Medicines Stakeholders Pledge Six-Month Hold Amid Confidence in Long-Term Growth
•
Everest Medicines (HKG: 1952), a Chinese pharmaceutical firm, has received commitments from its controlling shareholder CBridge Capital and executive directors Luo Yongqing and He Ying not to reduce their holdings for at least six months, according to a statement submitted to the Hong Kong Stock Exchange. This pledge reflects their…
-
Everest Medicines’ Velsipity NDA Accepted in Macau, Poised for First Asian Approval
•
Everest Medicines (HKG: 1952), based in China, has announced that its New Drug Application (NDA) for Velsipity (etrasimod) for the treatment of moderate-to-severe active ulcerative colitis (UC) has been accepted for review by the regulatory authority in Macau. This marks Macau as the first region in Asia, within Everest’s licensed…
-
BMS’s Azacitidine, First Oral AML Therapy, Reaches GBA Patients via Special Policy
•
Bristol-Myers Squibb (BMS, NYSE: BMY), a leading US pharmaceutical company, has announced the clinical application of its drug azacitidine in Shenzhen, within the Guangdong Hong Kong Macao Greater Bay Area (GBA). This marks the use of the world’s first and only oral maintenance therapy for acute myeloid leukemia (AML) in…
-
Guangdong Province Releases New Batch of Urgently Needed Drugs and Medical Devices for Greater Bay Area
•
The Medical Products Administration and Health Commission of Guangdong province have released the sixth batch of urgently needed imported drugs and medical devices for clinical use in the Guangdong-Hong Kong-Macao Greater Bay Area. This latest list includes two new drugs and ten medical devices, while also adding indications to one…
-
InnoCare Makes Minjuvi Combo Treatment Available to Patients in China’s GBA
•
InnoCare (HKG: 9969; SHA: 688428), a China-based biopharmaceutical company, has announced that the combination treatment of Minjuvi (tafasitamab) plus lenalidomide is now accessible to patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA).…
-
Guangdong Aims to Boost Biomedicine Industry with Incentives and Strategic Development
•
The Guangdong Provincial Development and Reform Commission has unveiled an ambitious set of measures aimed at fostering high-quality development in the biomedicine industry. The initiative seeks to propel Guangzhou’s biopharmaceutical sector to overcome challenges, enhance metropolitan coordination, and spearhead industry growth in the Greater Bay Area (GBA). The program extends…
-
China’s State Council Unveils 26 Initiatives to Enhance Grey-hair Economy
•
The State Council has unveiled the “Opinions on Developing the Grey-hair Economy to Boost Wellbeing of the Elderly,” outlining 26 initiatives aimed at enhancing the quality of life for the aging population through improved livelihood, product supply, industrial growth, and security measures. Key recommendations include the optimization of elderly health…
-
Hong Kong Aims for “First-Level Approvals” with New Drug Regulatory Institution
•
Hong Kong is taking steps to establish a drug regulatory institution that will permit “first-level approvals,” according to the Chief Executive’s Policy Address for 2023. This initiative means that drug and device market approval filings will be able to secure approval based on clinical data directly, without the need for…
-
Luye Pharma’s Lurbinectedin Receives Market Approval in Hong Kong for SCLC Treatment
•
China-based Luye Pharma Group (HKG: 2186) has announced that Hong Kong’s pharmacy and poisons board has approved a market approval filing for the company’s lurbinectedin (LY01017), a drug indicated for metastatic small-cell lung cancer (SCLC) in patients with tumor progression during or after platinum-based chemotherapy. The approval, facilitated by the…
-
Haplox and Illumina Mark Milestone with Production of NextSeq 2000Dx-CN-HAP Sequencing System in China
•
Haplox Biotechnology Co., Ltd, a Chinese biotech firm, and US industry leader Illumina (NASDAQ: ILMN) have jointly announced the production line completion of the first NextSeq 2000Dx-CN-HAP gene sequencing system, a domestically produced product manufactured in Shenzhen. The collaboration will now concentrate on local manufacturing of high-end life sciences equipment…
-
Fosun Pharma to Establish Greater Bay Area HQ in Shenzhen’s Pingshan District
•
Local media outlets report that Fosun International’s chairman, Guo Guangchang, announced at a business event in Shenzhen the establishment of a Greater Bay Area (GBA) headquarters for Fosun Pharma (HKG: 2196, SHA: 600196) in the Pingshan district of Shenzhen. This new site will serve as Fosun Pharma’s second global headquarters,…
-
China’s CDE Expands Market Approval Services with Two New Regional Windows
•
The China Center for Drug Evaluation (CDE) has announced the establishment of two additional external acceptance service windows at the National Medical Products Administration (NMPA) subcenters in the Yangtze River Delta and the Greater Bay Area. These service windows will commence operations from December 1, 2023, and will be responsible…
-
AstraZeneca to Open R&D Center in Hong Kong, Focusing on Cell and Gene Therapies
•
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has concluded a roughly 12-month discussion period with local authorities and is proceeding to establish a research and development (R&D) center in Hong Kong, marking a significant step as it becomes the first leading global Big Pharma to do so in the city.…
-
EC Healthcare Partners with Jiangxi Rimag Group to Expand Medical Imaging Services
•
China-based EC Healthcare (HKG: 2138) has entered into a partnership with Jiangxi Rimag Group Co., Ltd (HKG: 2522) to strengthen the development of medical imaging in the Greater Bay Area and to extend the medical imaging business from Hong Kong to other countries and regions. The financial details of the…
-
AstraZeneca Expands China Presence with Over 30 Agreements at CIIE
•
At the 6th China International Import Expo (CIIE) in Shanghai, UK-based pharmaceutical giant AstraZeneca plc (AZ; NASDAQ: AZN) has signed over 30 agreements with Chinese provincial governments and other entities, marking a significant expansion in China. The agreements include substantial investments and collaborations aimed at enhancing local production, improving access…
-
Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China’s GBA
•
Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with China-headquartered China Resources Guangdong Pharmaceutical Co., Ltd (CR Guangdong). This collaboration aims to leverage CR Guangdong’s logistics and supply chain management expertise to support the introduction of Teva’s migraine therapy, fremanezumab, in the Greater Bay…
-
Fosun Pharmaceutical to Acquire 14% Stake in UnitedHealthcare for USD 34 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to invest RMB 248.9 million (USD 34 million) in the acquisition of 97.22 million new shares of UnitedHealthcare, securing a 14% stake in the insurance firm. This strategic investment aims to diversify Fosun’s portfolio and enhance its presence in…
-
Novartis’s Aimovig Approved by China’s NMPA for Preventive Migraines Treatment
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its drug Aimovig (erenumab), a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb), which can now be used as a preventive treatment for adult migraines in China. Phase III…
-
Canton Biologics Secures Over RMB 300 Million in Series C Financing for Expansion
•
Canton Biologics Co., Ltd, a Guangzhou-based Contract Development and Manufacturing Organization (CDMO) specializing in biologic drugs, has reportedly raised over RMB 300 million (USD 27.5 million) in a Series C financing round. The round was led by SDIC Venture Capital, with additional investments from Guangdong Technology Financial Group, Taipu Life…
